Diatos, Drais deal

Diatos granted Drais exclusive, worldwide rights to develop and commercialize DTS-108 to treat solid tumors. The prodrug of SN38 delivered using Vectocell peptide-based intracellular delivery technology has completed preclinical development. Diatos could receive up to $46.9 million in an up front payment and milestones. The company also is eligible for royalties. SN38 is the active metabolite of irinotecan. ...